Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

Cardiologist Gregg Fonarow, MD, reviewed decades of data and discussed the long-term impact of the AHA's Get With The Guidelines-Stroke program.

A nationwide policy shift implemented in 2018 was designed to, among other things, improve the waiting list mortality rate. One unintended consequence, however, is that patients are now more likely to experience a stroke after receiving a new heart.

“Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,” one researcher said. Additional details will be presented at ACC.25 in Chicago.

Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5. 

Food insecurity—lacking consistent access to the food needed to live an “active, healthy lifestyle”—impacts up to one in eight Americans each year. 

Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.

Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.